<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02581007</url>
  </required_header>
  <id_info>
    <org_study_id>NSH 1132</org_study_id>
    <nct_id>NCT02581007</nct_id>
  </id_info>
  <brief_title>RIC Transplant Using Haplo Donors</brief_title>
  <official_title>Reduced Intensity Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northside Hospital, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Blood and Marrow Transplant Group of Georgia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northside Hospital, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will evaluate the safety and efficacy of a reduced intensity allogeneic HSCT from
      partially HLA-mismatched first-degree relatives utilizing PBSC as the stem cell source. The
      primary objective of the study is to estimate the incidence of graft rejection and acute
      GVHD. A secondary objective will be to estimate the incidence of the relapse, NRM, OS,
      chronic GVHD and EFS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will receive a haploidentical transpalnt using a fludarabine melphalan prepartive
      regimen. Patients will get cyclophosphamide on days 3 &amp; 4 post-transplant.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Graft Rejection</measure>
    <time_frame>100 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse incidence</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse incidence</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GVHD incidence</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GVHD incidence</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Chronic Myelogenous Leukemia</condition>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Acute Lymphocytic Leukemia</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Hodgkin's Lymphoma</condition>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <condition>Myelofibrosis</condition>
  <condition>CMML</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Reduced-Intensity Mismatched Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fludarabine, Melphalan &amp; Post-transplant cyclophosphamide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>fludarabine (30mg/m2) given every day starting on Day -6 through Day -2;</description>
    <arm_group_label>Reduced-Intensity Mismatched Transplant</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <arm_group_label>Reduced-Intensity Mismatched Transplant</arm_group_label>
    <other_name>melphalan (140mg/m2) given one time on Day -1.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>cyclophosphamide (50mg/kg) given every day starting on Day 3 through Day 4.</description>
    <arm_group_label>Reduced-Intensity Mismatched Transplant</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplant</intervention_name>
    <arm_group_label>Reduced-Intensity Mismatched Transplant</arm_group_label>
    <other_name>HSCT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  No available matched related or unrelated donor, OR a matched related or unrelated
             donor will not be available in time frame necessary to perform potentially curative
             transplant

          -  Availability of 3/6 - 5/6 matched (HLA-A, B, DR) related donor (donor must have
             negative HLA cross-match in host vs. graft direction)

          -  Karnofsky status â‰¥70%

          -  One of the following high-risk malignancies:

               1. Chronic Myelogenous Leukemia: Chronic myelogenous leukemia in chronic phase,
                  resistant or intolerant to available tyrosine kinase inhibitors; Chronic
                  myelogenous leukemia in accelerated phase; Chronic myelogenous leukemia with
                  blast crisis that has entered into a second chronic phase following induction
                  chemotherapy

               2. Acute Myelogenous Leukemia in first or greater remission

               3. Myelodysplastic Syndrome at least one of the following: treatment-related;
                  monosmy 7, complex cytogenetics or other high risk karyotype; IPSS score of 1.0
                  or greater; neutropenia or cytopenia requiring transfusion not responding to
                  therapy; peripheral or BM blast count of &lt;10%; CMML

               4. Acute lymphocytic leukemia/lymphoblastic lymphoma: 2nd or subsequent complete
                  remission; first complete remission; marrow blasts &lt;5%, but persistence of
                  minimal residual disease by flow cytometry, cytogenetics, or FISH

               5. Chronic Lymphocytic Leukemia/Prolymphocytic Leukemia: previously treated disease
                  that has either relapsed or failed to respond adequately to conventional-dose
                  therapy including purine analogs

               6. Hodgkin's or Non-Hodgkin's Lymphoma (including low-grade, mantle cell, and
                  intermediate-grade/diffuse): previously treated disease that has either relapsed
                  or failed to respond adequately to conventional-dose therapy or autologous
                  transplantation

               7. Myeloproliferative diseases (myelofibrosis, CMML)

               8. Multiple Myeloma with relapse after a prior autologous transplant or eligible for
                  allogeneic HSCT based on other risk factors

        Exclusion Criteria:

          -  not be excluded on basis of sex, racial, or ethnic backgrounds

          -  poor cardiac function: left ventricular ejection fraction &lt;40%

          -  poor pulmonary function: FEV1 and FVC &lt;50% predicted

          -  poor liver function: bilirubin &gt;2 mg/dl (not due to hemolysis, Gilbert's or primary
             malignancy)

          -  poor renal function: Creatinine &gt;2.0mg/dl or creatinine clearance (calculated
             creatinine clearance is permitted) &lt; 40 mL/min based on Traditional Cockcroft-Gault
             formula: 140 - age (yrs) x Smaller of Actual Weight vs. Ideal Body Weight (kg) / 72 x
             Serum creatinine (mg/dl)

          -  HIV-positive

          -  prior allogeneic transplant

          -  women of childbearing potential who currently are pregnant or who are not practicing
             adequate contraception

          -  any debilitating medical or psychiatric illness which would preclude their giving
             informed consent or their receiving optimal treatment and follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melhem Solh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northside Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melhem Solh, MD</last_name>
    <phone>404-255-1930</phone>
    <email>msolh@bmtga.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stacey Brown</last_name>
    <phone>404-851-8238</phone>
    <email>stacey.brown@Northside.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Northside Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S, Felicini R, Falcinelli F, Velardi A, Ruggeri L, Aloisi T, Saab JP, Santucci A, Perruccio K, Martelli MP, Mecucci C, Reisner Y, Martelli MF. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol. 2005 May 20;23(15):3447-54. Epub 2005 Mar 7.</citation>
    <PMID>15753458</PMID>
  </reference>
  <reference>
    <citation>Bashey A, Solomon SR. T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor. Bone Marrow Transplant. 2014 Aug;49(8):999-1008. doi: 10.1038/bmt.2014.62. Epub 2014 May 19. Review.</citation>
    <PMID>24842530</PMID>
  </reference>
  <reference>
    <citation>O'Donnell PV, Luznik L, Jones RJ, Vogelsang GB, Leffell MS, Phelps M, Rhubart P, Cowan K, Piantados S, Fuchs EJ. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002;8(7):377-86.</citation>
    <PMID>12171484</PMID>
  </reference>
  <reference>
    <citation>Solomon SR, Sizemore CA, Sanacore M, Zhang X, Brown S, Holland HK, Morris LE, Bashey A. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow Transplant. 2012 Dec;18(12):1859-66. doi: 10.1016/j.bbmt.2012.06.019. Epub 2012 Aug 1.</citation>
    <PMID>22863841</PMID>
  </reference>
  <reference>
    <citation>Solomon SR, Sizemore CA, Sanacore M, Zhang X, Brown S, Holland HK, Morris LE, Bashey A. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors. Biol Blood Marrow Transplant. 2015 Jul;21(7):1299-307. doi: 10.1016/j.bbmt.2015.03.003. Epub 2015 Mar 19.</citation>
    <PMID>25797174</PMID>
  </reference>
  <results_reference>
    <citation>Szydlo R, Goldman JM, Klein JP, Gale RP, Ash RC, Bach FH, Bradley BA, Casper JT, Flomenberg N, Gajewski JL, Gluckman E, Henslee-Downey PJ, Hows JM, Jacobsen N, Kolb HJ, Lowenberg B, Masaoka T, Rowlings PA, Sondel PM, van Bekkum DW, van Rood JJ, Vowels MR, Zhang MJ, Horowitz MM. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol. 1997 May;15(5):1767-77.</citation>
    <PMID>9164184</PMID>
  </results_reference>
  <results_reference>
    <citation>Anasetti C, Amos D, Beatty PG, Appelbaum FR, Bensinger W, Buckner CD, Clift R, Doney K, Martin PJ, Mickelson E, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med. 1989 Jan 26;320(4):197-204.</citation>
    <PMID>2643045</PMID>
  </results_reference>
  <results_reference>
    <citation>Kernan NA, Flomenberg N, Dupont B, O'Reilly RJ. Graft rejection in recipients of T-cell-depleted HLA-nonidentical marrow transplants for leukemia. Identification of host-derived antidonor allocytotoxic T lymphocytes. Transplantation. 1987 Jun;43(6):842-7.</citation>
    <PMID>3296349</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2015</study_first_submitted>
  <study_first_submitted_qc>October 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2015</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CML</keyword>
  <keyword>AML</keyword>
  <keyword>MDS</keyword>
  <keyword>ALL</keyword>
  <keyword>CLL/CPL</keyword>
  <keyword>HD</keyword>
  <keyword>NHL</keyword>
  <keyword>MPS</keyword>
  <keyword>CMML</keyword>
  <keyword>MM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

